Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 887-895

  Camfield, David A ^a   Sarris, Jerome ^a,b   Berk, Michael ^b,c,d,e  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

Author keywords

Glutamate; Nutraceuticals; Obsessive Compulsive Disorder; Serotonin; Treatment

Indexed keywords

ACETYLCYSTEINE; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLYCINE; INOSITOL; NUTRACEUTICAL; PAROXETINE; PLACEBO; PLANT MEDICINAL PRODUCT; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILYBUM MARIANUM EXTRACT; TRYPTOPHAN; VENLAFAXINE;

ANXIETY; BIPOLAR DISORDER; BLOATING; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERICUM PERFORATUM; INSOMNIA; LIBIDO DISORDER; NAUSEA; NEUROBIOLOGY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PLANT LEAF; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SILYBUM MARIANUM; TIME TO MAXIMUM PLASMA CONCENTRATION; TRICHOTILLOMANIA; UNSPECIFIED SIDE EFFECT;

5-HYDROXYTRYPTOPHAN; ACETYLCYSTEINE; DIETARY SUPPLEMENTS; GLYCINE; HUMANS; HYPERICUM; INOSITOL; MILK THISTLE; OBSESSIVE-COMPULSIVE DISORDER; PLANT PREPARATIONS; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 79956004865     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.02.011     Document Type: Review

References (123)

1. Abramowitz J.S. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997, 65:44-52.
2. Albelda N., Bar-On N., Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology 2010, 210:13-24.
3. Allegra L., Dal Sasso M., Bovio C., Massoni C., Fonti E., Braga P.C. Human neutrophil oxidative bursts and their in vitro modulation by different N-Acetylcysteine concentrations. Arzneim-Forsch 2002, 52:669-676.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC. Fourth Edition.
5. Atkuri K.R., Mantovani J.J., Herzenberg L.A. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007, 7:355-359.
6. Baker D.A., Xi Z.X., Shen H., Swanson C.J., Kalivas P.W. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002, 22:9134-9141.
7. Barr L.C., Goodman W.K., Price L.H. The serotonin hypothesis of obsessive compulsive disorder. Int Clin Psychopharmacol 1993, 8:79-82.
8. Behl A., Swami G., Sircar S.S., Bhatia M.S., Banerjee B.D. Relationship of possible stress-related biochemical markers to oxidative/antioxidative status in obsessive-compulsive disorder. Neuropsychobiology 2010, 61:210-214.
9. Bellodi L., Erzegovesi S., Bianchi L., Lucini V., Conca R., Lucca A. Plasma tryptophan levels and tryptophan/neutral amino acid ratios in obsessive-compulsive patients with and without depression. Psychiatry Res 1997, 69:9-15.
10. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008, 64:361-368.
11. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64:468-475.
12. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci 2008, 29:346-351.
13. Berk M., Jeavons S., Dean O.M., Dodd S., Moss K., Gama C.S., et al. Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting. CNS Spectr 2009, 14:357-360.
14. Birdsall T.C. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998, 3:271-280.
15. Bobes J., González M.P., Bascarán M.T., Arango C., Sáiz P.A., Bousoño M. Quality of life and disability in patients with obsessive compulsive disorder. Eur Psychiatry 2001, 16:239-245.
16. Bolton J., Moore G.J., MacMillan S., Stewart C.M., Rosenberg D.R. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry 2001, 40:903-906.
17. Bonanomi L., Gazzaniga A. Toxicology, pharmacokinetics and metabolism of acetylcysteine. Eur J Respir Dis 1980, 111:45-51.
18. Brown R.R. Tryptophan metabolism: a review. L-Tryptophan: Current Prospects in Medicine and Drug Safety 1994, 17-30. Walter de Gruyter, Berlin. W. Kochen, H. Steinhart (Eds.).
19. Butterweck V., Schmidt M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007, 157:356-361.
20. Carey P.D., Warwick J., Harvey B.H., Stein D.J., Seedat S. Single Photon Emission Computed Tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. Metab Brain Dis 2004, 19:125-134.
21. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30:1735-1740.
22. Chakraborty S., Singh O.P., Dasgupta A., Mandal N., Das H.N. Correlation between lipid peroxidation-induced TBARS level and disease severity in obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:363-366.
23. Clements R.S., Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr 1980, 33:1954-1967.
24. Clements J.D., Westbrook G.L. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron 1991, 7:605-613.
25. Cleveland W.L., DeLaPaz R.L., Fawwaz R.A., Challop R.S. High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period. Neural Plast 2009, 2009:768398.
26. Coşkun Ş., Özer Ç., Gönül B., Take G., Erdo an D. The effect of repeated tryptophan administration on body weight, food intake, brain lipid peroxidation and serotonin immunoreactivity in mice. Mol Cell Biochem 2006, 286:133-138.
27. Crino R., Slade T., Andrews G. The changing prevalence and severity of obsessive-compulsive disorder criteria from DSM-III to DSM-IV. Am J Psychiatry 2005, 162:876-882.
28. De Rosa S.C., Zaretsky M.D., Dubs J.G., Roederer M., Anderson M., Green A., et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Investig 2000, 30:915-929.
29. Dean O., Giorlando F., Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2010, 35. [Epub ahead of print].
30. Dell'Osso B., Nestadt G., Allen A., Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006, 67:600-610.
31. Denys D., Van Nieuwerburgh F., Deforce D., Westenberg H.G.M. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 2007, 68:747-753.
32. Eaton W.W., Martins S.S., Nestadt G., Bienvenu O.J., Clarke D., Alexandre P. The burden of mental disorders. Epidemiol Rev 2008, 30:1-14.
33. Einat H., Belmaker R.H. The effects of inositol treatment in animal models of psychiatric disorders. J Affect Disord 2001, 62:113-121.
34. Einat H., Clenet F., Shaldubina A., Belmaker R.H., Bourin M. The antidepressant activity of inositol in the forced swim test involves 5-HT2 receptors. Behav Brain Res 2001, 118:77-83.
35. Ersan S., Bakir S., Erdal Ersan E., Dogan O. Examination of free radical metabolism and antioxidant defence system elements in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1039-1042.
36. Feldman R.S., Meyer J.S., Quenzer L.F. Principles of Neuropsychopharmacology 1997.
37. Fineberg N.A., Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 2005, 8:107-129.
38. Fisher S.K., Heacock A.M., Agranoff B.W. Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 1992, 58:18-38.
39. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005, 162:151-161.
40. Frey R., Metzler D., Fischer P., Heiden A., Scharfetter J., Moser E., et al. Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. J Psychiatr Res 1998, 32:411-420.
41. Fux M., Levine J., Aviv A., Belmaker R.H. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996, 153:1219-1221.
42. Fux M., Benjamin J., Belmaker R.H. Inositol versus placebo aumentation of serotonin reuptake inhibitor in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol 1999, 2:193-195.
43. Gendle M.H., Golding A.C. Oral administration of 5-hydroxytryptophan (5-HTP) impairs decision making under ambiguity but not under risk: Evidence from the Iowa Gambling Task. Hum Psychopharmacol 2010, 25:491-499.
44. Goddard A.W., Shekhar A., Whiteman A.F., McDougle C.J. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 2008, 13:325-332.
45. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989, 46:1012-1016.
46. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use and reliability. Arch Gen Psychiatry 1989, 46:1006-1011.
47. Grant J.E., Odlaug B.L., Suck W.K. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009, 66:756-763.
48. Greenberg W.M., Benedict M.M., Doerfer J., Perrin M., Panek L., Cleveland W.L., et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res 2009, 43:664-670.
49. Harvey B.H. The neurobiology and pharmacology of depression. A comparative overview of serotonin selective antidepressants. S Afr Med J 1997, 87.
50. Harvey B.H., Scheepers A., Brand L., Stein D.J. Chronic inositol increases striatal D2 receptors but does not modify dexamphetamine-induced motor behavior - relevance to obsessive-compulsive disorder. Pharmacol Biochem Behav 2001, 68:245-253.
51. Harvey B.H., Brink C.B., Seedat S., Stein D.J. Defining the neuromolecular action of myo-inositol: application to obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:21-32.
52. Hasselbalch S.G., Hansen E.S., Jakobsen T.B., Pinborg L.H., Lønborg J.H., Bolwig T.G. Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 2007, 115:388-394.
53. Hesse S., Müller U., Lincke T., Barthel H., Villmann T., Angermeyer M.C., et al. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res Neuroimaging 2005, 140:63-72.
54. Hrdina P.D., Demeter E., Vu T.B., Sotonyi P., Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 1993, 614:37-44.
55. Javitt D.C. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 2006, 19:151-157.
56. Javitt D.C., Balla A., Burch S., Suckow R., Xie S., Sershen H. Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004, 29:300-307.
57. Jenike M.A. An update on obsessive-compulsive disorder. Bull Menninger Clin 2001, 65:4-25.
58. Jenike M.A. Obsessive-compulsive disorder. N Engl J Med 2004, 350:259-265.
59. Jenike M.A., Baer L., Minichiello W.E. Obsessive-compulsive disorders: practical management 1998, 3rd ed.
60. Kalra E.K. Nutraceutical - definition and introduction. AAPS PharmSci 2003, 5.
61. Kim H., McGrath B.M., Silverstone P.H. A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders - focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol 2005, 20:309-326.
62. Kobak K.A., Taylor L.V., Bystritsky A., Kohlenberg C.J., Greist J.H., Tucker P., et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005, 20:299-304.
63. Konuk N., Tekin I.O., Ozturk U., Atik L., Atasoy N., Bektas S., et al. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediat Inflamm 2007, 2007.
64. Lafleur D.L., Pittenger C., Kelmendi B., Gardner T., Wasylink S., Malison R.T., et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 2006, 184:254-256.
65. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 1997, 7:147-155.
66. Levine J., Mishori A., Susnosky M., Martin M., Belmaker R.H. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry 1999, 45:270-273.
67. Lu P., Mamiya T., Lu L., Mouri A., Niwa M., Kim H.C., et al. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res 2010, 207:387-393.
68. Marazziti D., Masala I., Rossi A., Hollander E., Presta S., Giannaccini G., et al. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Neuropsychobiology 2000, 41:171-177.
69. Marazziti D., Dell'Osso L., Masala I., Baroni S., Presta S., Giannaccini G., et al. Decreased inhibitory activity of PKC in OCD patients after six months of treatment. Psychoneuroendocrinology 2002, 27:769-776.
70. Mazzio E.A., Harris N., Soliman K.F.A. Food constituents attenuate monoamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 1998, 64:603-606.
71. Menzies L., Chamberlain S.R., Laird A.R., Thelen S.M., Sahakian B.J., Bullmore E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci Biobehav Rev 2008, 32:525-549.
72. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., DaSilva J., et al. The effect of paroxetine on 5-HT2A receptors in depression: an [18F] setoperone PET imaging study. Am J Psychiatry 2001, 158:78-85.
73. Meyer J.H., McMain S., Kennedy S.H., Korman L., Brown G.M., DaSilva J.N., et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003, 160:90-99.
74. Meyers S. Use of neurotransmitter precursors for treatment of depression. Altern Med Rev 2000, 5:64-71.
75. Moore G.J., MacMaster F.P., Stewart C., Rosenberg D.R. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998, 37:663-667.
76. Moran M.M., Melendez R., Baker D., Kalivas P.W., Seamans J.K. Cystine/Glutamate Antiporter Regulation of Vesicular Glutamate Release 2003, 445-447.
77. Moran M.M., McFarland K., Melendez R.I., Kalivas P.W., Seamans J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005, 25:6389-6393.
78. Nathan P.J. Hypericum perforatum (St John's wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 2001, 15:47-54.
79. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
80. Odlaug B.L., Grant J.E. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007, 27:227-229.
81. Oliet S.H.R., Mothet J.P. Regulation of N-methyl-d-aspartate receptors by astrocytic d-serine. Neuroscience 2009, 158:275-283.
82. Osuchowski M.F., Johnson V.J., He Q., Sharma R.P. Alterations in regional brain neurotransmitters by silymarin, a natural antioxidant flavonoid mixture, in BALB/c mice. Pharm Biol 2004, 42:384-389.
83. Ozdemir E., Cetinkaya S., Ersan S., Kucukosman S., Ersan E.E. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:62-65.
84. Pallanti S., Hollander E., Bienstock C., Koran L., Leckman J., Marazziti D., et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002, 5:181-191.
85. Pandey G.N., Pandey S.C., Janicak P.G., Marks R.C., Davis J.M. Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990, 28:215-222.
86. Pandey S.C., Davis J.M., Pandey G.N. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci 1995, 20:215-225.
87. Pato M.T., Zohar-Kadouch R., Zohar J., Murphy D.L. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988, 145:1521-1525.
88. Pendyala L., Creaven P.J. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a Phase I trial. Cancer Epidemiol Biomark Prev 1995, 4:245-251.
89. Pittenger C., Bloch M., Wegner R., Teitelbaum C., Krystal J.H., Coric V. Glutamatergic dysfunction in obsessive-compulsive disorder and the potential clinical utility of glutamate-modulating agents. Prim Psychiatry 2006, 13:65-77.
90. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
91. Pow D.V. Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate. Glia 2001, 34:27-38.
92. Rahimi R., Nikfar S., Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:118-127.
93. Rosenberg D.R., Macmaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000, 39:1096-1103.
94. Rosenberg D.R., Amponsah A., Sullivan A., MacMillan S., Moore G.J. Increased medial thalamic choline in pediatric obsessive-compulsive disorder as detected by quantitative in vivo spectroscopic imaging. J Child Neurol 2001, 16:636-641.
95. Rosenberg D.R., MacMillan S.N., Moore G.J. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol 2001, 4:179-190.
96. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry 2004, 43:1146-1153.
97. Ruscio A.M., Stein D.J., Chiu W.T., Kessler R.C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010, 15:53-63.
98. Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res 2007, 21:703-716.
99. Sarris J., Kavanagh D.J. Kava and St John's wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med 2009, 15:827-836.
100. Sarris J., Kavanagh D., Byrne G. Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. J Psychiatr Res 2010, 44:32-41.
101. Saxena S., Brody A.L., Schwartz J.M., Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998, 26-37.
102. Saxena S., Bota R.G., Brody A.L. Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry 2001, 6:82-101.
103. Sayyah M., Boostani H., Pakseresht S., Malayeri A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:362-365.
104. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001, 299:12-20.
105. Seedat S., Stein D.J. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol 1999, 14:353-356.
106. Seedat S., Stein D.J., Harvey B.H. Inositol in the treatment of trichotillomania and compulsive skin picking [5]. J Clin Psychiatry 2001, 62:60-61.
107. Singer H.S., Morris C., Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74:862-867.
108. Sirek A., Sirek O.V. Serotonin: a review. Can Med Assoc J 1970, 102:846-849.
109. Slade T., Johnston A., Oakley Browne M.A., Andrews G., Whiteford H. 2007 National Survey of Mental Health and Wellbeing: Methods and key findings. Aust NZ J Psychiatry 2009, 43:594-605.
110. Smeraldi E., Diaferia G., Erzegovesi S., Lucca A., Bellodi L., Moja E.A. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry 1996, 40:398-402.
111. Smith Q.R. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 2000, 130.
112. Steiner M. Long-term treatment and prevention of relapse of OCD with paroxetine. 148th Annual Meeting of the American Psychiatric Association 1995, 150.
113. Stengler-Wenzke K., Müller U., Angermeyer M.C., Sabri O., Hesse S. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci 2004, 254:252-255.
114. Taylor L.H., Kobak K.A. An open-label trial of St. John's Wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000, 61:575-578.
115. Tolin D.F., Abramowitz J.S., Diefenbach G.J. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. J Clin Psychiatry 2005, 66:1549-1557.
116. Turner E.H., Loftis J.M., Blackwell A.D. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006, 109:325-338.
117. U.S.Department of Agriculture USDA National Nutrient Database for Standard Reference, Release 23 2010, Agricultural Research Service.
118. Whiteside S.P., Port J.D., Abramowitz J.S. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res Neuroimaging 2004, 132:69-79.
119. Wright R.A., Arnold M.B., Wheeler W.J., Ornstein P.L., Schoepp D.D. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 2001, 298:453-460.
120. Yaryura Tobias J.A., Bhagavan H.N. L-Tryptophan in obsessive compulsive disorders. Am J Psychiatry 1977, 134:1298-1299.
121. Yates M., Leake A., Candy J.M., Fairbairn A.F., McKeith I.G., Ferrier I.N. 5HT2 receptor changes in major depression. Biol Psychiatry 1990, 27:489-496.
122. Yatham L.N., Liddle P.F., Dennie J., Shiah I.S., Adam M.J., Lane C.J., et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 1999, 56:705-711.
123. Zmilacher K., Battegay R., Gastpar M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988, 20:28-35.